AIM IP specialist Tekcapital to sell or float all four portfolio companies 'within 2 years'. Watch the full video here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksNetscientific Share News (NSCI)

Share Price Information for Netscientific (NSCI)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 53.50
Bid: 52.00
Ask: 55.00
Change: 0.00 (0.00%)
Spread: 3.00 (5.77%)
Open: 55.00
High: 55.00
Low: 53.50
Yest. Close: 55.00
NSCI Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

RNS Alerts are a premium feature

Login to your account

myTerminal is a premium feature

Login to your account

Don't have an account? Click here to register.

NetScientific acquires rest of ProAxsis for £0.23m

Fri, 16th Oct 2020 09:54

(Sharecast News) - Life sciences and technology commercialisation and investment company NetScientific has agreed to acquire the outstanding minority interest of 43.6% of its portfolio company ProAxsis, it announced on Friday, from QUBIS and the founders.
The AIM-traded firm said the cash consideration would be £0.23m, with the key patent being assigned by the sellers.

It described ProAxsis as a commercial-stage diagnostics company, based in Northern Ireland, with a "rapidly growing" global client list of pharmaceutical companies and academic laboratories.

The company has registered a CE-mark for activity-based immunoassays targeting Neutrophil Elastase (NE) and Proteinase 3, as biomarkers of lung infection and inflammation in chronic respiratory diseases such as COPD, cystic fibrosis and bronchiectasis.

That technology had been translated into a point-of-care test, 'NEATstik', to enable ongoing monitoring of active NE levels.

In the year ended 31 December, ProAxsis generated revenues of £0.73m, and a loss after tax for the financial year of £0.18m, of which £52,178 was included with non-controlling interests.

Its net liabilities as at the end of 2019 totalled £2.4m, of which £1.05m was included with non-controlling interests.

Following the acquisition, ProAxsis would be fully consolidated within NetScientific, with no amounts included with non-controlling interests, and operate as a separate subsidiary.

"In line with the group's strategic review and stated plans, ProAxsis is an example of the strong commercialisation potential of spin out companies from UK universities such as Queen's University Belfast," said chief executive officer Dr Ilian Iliev.

"This provides an early investment realisation opportunity for the company's two co-founders, Professor Lorraine Martin and Professor Brian Walker, while allowing the company to continue and accelerate its growth."

Dr Iliev said that, in line with the company's "proactive management", increasing its stake in ProAxsis via the agreements would enable it to provide the support required to maximise the company's value, and help it "capture synergies" within its broader ecosystem in the growing sector.

"We are delighted that David Moore, the university's head of spinouts and investments at QUBIS, has agreed to remain on the ProAxsis board of directors for the foreseeable future."

At 0947 BST, shares in NetScientific were up 1.64% at 62p.

More News

TRADING UPDATES: Beximco's India jab mire; Lamprell gets Aramco deal

TRADING UPDATES: Beximco's India jab mire; Lamprell gets Aramco deal

28 Apr 21 14:04

TRADING UPDATES: Aquis maiden full-year profit; Tern turns to profit

TRADING UPDATES: Aquis maiden full-year profit; Tern turns to profit

31 Mar 21 15:33

IN BRIEF: NetScientific's vaccine consortium gains funding commitment

IN BRIEF: NetScientific's vaccine consortium gains funding commitment

11 Mar 21 19:10

IN BRIEF: NetScientific Says Blanver Joins Covid Vaccine Consortium

IN BRIEF: NetScientific Says Blanver Joins Covid Vaccine Consortium

23 Feb 21 16:55

NetScientific's ProAxsis Inks Licensing Deal With University Of Geneva

NetScientific's ProAxsis Inks Licensing Deal With University Of Geneva

22 Feb 21 09:30

IN BRIEF: NetScientific Shares Restored After Drug Trial Announcement

IN BRIEF: NetScientific Shares Restored After Drug Trial Announcement

3 Feb 21 19:18

IN BRIEF: NetScientific Shares Suspended Pending Notification

IN BRIEF: NetScientific Shares Suspended Pending Notification

2 Feb 21 14:21

UK TRADING UPDATE SUMMARY: Novacyt Tests Can Spot New Virus Strain

UK TRADING UPDATE SUMMARY: Novacyt Tests Can Spot New Virus Strain

21 Dec 20 18:10

IN BRIEF: NetScientific's ProAxisis Wins Innovate UK Grant For Project

IN BRIEF: NetScientific's ProAxisis Wins Innovate UK Grant For Project

11 Dec 20 21:39

NetScientific's ProAxsis gets grant for Covid-19 project

(Sharecast News) - Technology commercialisation company NetScientific announced on Thursday that its portfolio company ProAxsis has been awarded a high impact Innovate UK grant, as part of the recent 'UKRI Ideas to Address Covid-19' competition.

10 Dec 20 15:35

IN BRIEF: NetScientific Subsidiary Leads Financing Round In SageTech

IN BRIEF: NetScientific Subsidiary Leads Financing Round In SageTech

30 Nov 20 18:18

IN BRIEF: NetScientific's ProAxsis Partners Up With DiaPharma

IN BRIEF: NetScientific's ProAxsis Partners Up With DiaPharma

19 Nov 20 20:21

NetScientific's ProAxsis appoints North American distributor

(Sharecast News) - Life sciences, technology investment and commercialisation company NetScientific announced on Thursday that its portfolio company ProAxsis has appointed DiaPharma Group as the exclusive distributor of its portfolio of respiratory research assays for the key North America region.

19 Nov 20 16:28

UK TRADING UPDATE SUMMARY: Mereo To Delist From AIM Amid Nasdaq Focus

UK TRADING UPDATE SUMMARY: Mereo To Delist From AIM Amid Nasdaq Focus

11 Nov 20 20:17

UK TRADING UPDATE SUMMARY: Newly-Listed Wheaton Reports Bumper Quarter

UK TRADING UPDATE SUMMARY: Newly-Listed Wheaton Reports Bumper Quarter

10 Nov 20 17:40

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.